Skip to main content
. 2016 Jan 4;127(10):1269–1275. doi: 10.1182/blood-2015-10-674242

Table 4.

Factors predictive for MMR at 12 months (optimal response) including the type of BCR-ABL fusion transcript

No MMR, N (%) MMR, N (%) OR 95% CI OR P
Univariate*
 TKI type
  Imatinib 400 20 (23) 24 (8)
  Imatinib 800 33 (38) 140 (45) 3.54 (1.75-7.15) <.001
  Dasatinib 22 (25) 72 (23) 2.73 (1.27-5.84) .010
  Nilotinib 11 (13) 77 (25) 5.83 (2.45-13.88) <.001
 Transcript type
  e13a2 60 (70) 101 (32)
  e14a2 15 (17) 151 (48) 5.98 (3.22-11.11) <.001
  Both 11 (13) 61 (19) 3.29 (1.61-6.75) .001
 Splenomegaly (≥10 cm)
  No 76 (88) 300 (96)
  Yes 10 (12) 13 (4) 0.33 (0.14-0.78) .012
 Platelets (>300 K/µL)
  No 46 (53) 123 (39)
  Yes 40 (46) 190 (61) 1.78 (1.10-2.87) .019
Multivariate§
 TKI type
  Imatinib 400 20 (23) 24 (8)
  Imatinib 800 33 (38) 140 (45) 4.83 (2.20-10.62) <.001
  Dasatinib 22 (25) 72 (23) 3.39 (1.45-7.89) .005
  Nilotinib 11 (13) 77 (25) 8.24 (3.16-21.43) <.001
 Transcript type
  e13a2 60 (70) 101 (32)
  e14a2 15 (17) 151 (48) 5.85 (3.01-11.37) <.001
  Both 11 (13) 61 (19) 3.18 (1.50-6.74) .003
*

White blood cell count, age, Sokal score, hemoglobin, peripheral blood blasts, and serum lactate dehydrogenase are not significant (P = not significant; data not shown).

Imatinib 400 is the reference for comparison with the other 3 TKI modalities.

e13a2 is the reference for comparison with e14a2 and both (coexpressed transcripts).

§

Platelet count and spleen size were not significant in multivariate analysis (data not shown).